POZ Community Forums
Main Forums => Living With HIV => Topic started by: bimazek on January 03, 2009, 03:25:49 am
-
If U have taken any monoclonal antibody to treat any disease-- usually a cancer, or transplant rejection or auto immune, or T cell CD3 Receptor inhibitor, or Respiratory Syncytial Virus (RSV) or lymphoma, etc see complete list below then PLEASE POST -your experiences with these meds only if you had hiv at the time, i am curious about the effect on how you felt, your body, cd4 counts up or down, did doctor say anything about them being good or bad regarding hiv infection.
I have not seen any info and am curious to hear peoples first hand experience, supposedly they are tolerable for general population
Did you have any good or bad experiences on them, were you on HAART at the time or was it before you started haart
all these drugs end in letters...... mab for example Abciximab,
mab
FDA-approved therapeutic monoclonal antibody
FDA approved therapeutic antibodies
The first FDA-approved therapeutic monoclonal antibody was a murine IgG2a CD3 specific transplant rejection drug, Muromonab (OKT-3), in 1986. Currently, twenty-one FDA-approved therapies exist, and hundreds of therapies are undergoing clinical trials. Most are concerned with immunological and oncological targets.
FDA approved monoclonal antibodies
Antibody Brand name Approval date Type Target Approved treatment(s)
Abciximab ReoPro 1994 inhibition of glycoprotein IIb/IIIa Cardiovascular disease
Adalimumab Humira 2002 inhibition TNF-a Inflammatory diseases (auto-immune disorders)
Alemtuzumab Campath 2001 humanized CD52 Chronic lymphocytic leukemia
Basiliximab Simulect 1998 chimeric IL-2 receptor a Transplant rejection
Bevacizumab Avastin 2004 humanized vascular endothelial growth factor Colorectal cancer
Cetuximab Erbitux 2004 chimeric epidermal growth factor receptor Colorectal cancer
Daclizumab Zenapax 1997 humanized IL-2 receptor a Transplant rejection
Eculizumab Soliris 2007 humanized complement system protein C5 Inflammatory diseases including paroxysmal nocturnal hemoglobinuria
Efalizumab Raptiva 2002 humanized CD11a acute myelogenous leukemia-linked to a cytotoxic agent, calicheamicin
(99mTc) Fanolesomab NeutroSpec 2002 humanized CD15 anti-CD15 antibodies bind selectively to neutrophils, it could be used to localize the site of an infection
Gemtuzumab Mylotarg 2001 humanized CD33 Inflammatory diseases (psoriasis)
Ibritumomab tiuxetan Zevalin 2002 murine CD20 Non-Hodgkin lymphoma (with yttrium-90 or indium-111)
Infliximab Remicade 1998 chimeric inhibition of TNF-a signalling Inflammatory diseases (mostly auto-immune disorders)
111In-capromab Erbitux 2004 chimeric Prostate-specific antigen (PSA) localize and stage a new or recurrent prostate cancer
Imciromab Myoscint 1996 chimeric myosin(in heart) radioimmune conjugate - Indium In 111 imciromab pentetate-used for radiodiagnostic imaging of dead heart tissue
Muromonab-CD3 Orthoclone OKT3 1986 murine T cell CD3 Receptor Transplant rejection
Natalizumab Tysabri 2006 humanized T cell VLA4 receptor Inflammatory diseases (mainly autoimmune-related multiple sclerosis therapy)
Omalizumab Xolair 2004 humanized immunoglobulin E (IgE) Inflammatory diseases (mainly allergy-related asthma therapy)
Palivizumab Synagis 1998 humanized an epitope of the F protein of RSV Viral infection (especially Respiratory Syncytial Virus (RSV)
Panitumumab Vectibix 2006 human epidermal growth factor receptor Colorectal cancer
Ranibizumab Lucentis 2006 humanized vascular endothelial growth factor Macular degeneration
Gemtuzumab ozogamicin Mylotarg 2000 humanized CD33 Acute myelogenous leukemia (with calicheamicin)
Rituximab Rituxan, Mabthera 1997 chimeric CD20 Non-Hodgkin lymphoma
Tositumomab Bexxar 2003 murine CD20 Non-Hodgkin lymphoma
Trastuzumab Herceptin 1998 humanized ErbB2 Breast cancer